Coronavirus drug maker SciClone Pharma eyes Hong Kong IPO
myskin - stock.adobe.com
SciClone Pharmaceutical (Holdings), a Chinese biopharmaceutical company that claims to have developed a drug to treat Covid-19, is seeking the greenlight to list in Hong Kong.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: